ALNYNASDAQ— Alnylam Pharmaceuticals Inc Price & Analysis

Alnylam Pharmaceuticals Inc

HEALTHCARE — BIOTECHNOLOGY

$266.11

+$1.61+0.61%

Market Cap: $35.78B; Large Cap
P/E Ratio: 42.92; Fwd: 19.27
EPS (TTM): $6.23
Div. Yield: N/A

Technical Summary

RSI (14)62.18Neutral

SMA (50)$258.83Bullish

SMA (200)$321.14Bearish

MACD2.4633Bullish

Bollinger$209.59 – $265.69Upper

Stochastic90.32Overbought

Theo Outlook

Alnylam Pharmaceuticals presents a bullish thesis with a market capitalization of $35.6 billion, a trailing P/E of 46.28, EPS of $5.75, and robust 66.9% year-over-year quarterly revenue growth, reflecting strong commercial traction in its RNAi platform despite the premium valuation. The company's profitability metrics, including a 16.1% profit margin and 96.6% return on equity, underscore improving operational leverage as its therapies scale. This positions ALNY for continued upside as revenue expands from its core pipeline.

Key catalysts include ongoing commercialization of RNAi therapies targeting rare diseases, with recent quarterly revenue momentum at $4.8 billion TTM and analyst ratings showing 7 strong buy and 16 buy recommendations alongside a $370.20 target price. Expansion into broader indications and potential new product launches could drive further earnings growth, supported by the company's focus on RNA interference innovation and positive analyst sentiment.

Risks encompass regulatory hurdles for biotech approvals, intense competition in the RNAi space, and macroeconomic pressures such as interest rate sensitivity affecting high-growth healthcare valuations. Mitigations include ALNY's established pipeline, high institutional ownership at 101.7%, and diversified revenue streams that provide resilience against single-product setbacks. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Analysis generated by HeyTheo AI on Sep 7, 2026.

Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.

Fundamental Snapshot

Revenue: $4.80B
EBITDA: $1.05B
Gross Profit: $3.83B
Operating Margin: 17.9%
Profit Margin: 16.1%
ROE: 96.6%
Book Value: $10.12
Beta: 0.28
52-Wk High: $495.55
52-Wk Low: $197.81
Avg Volume: 1.42M
PEG Ratio: 0.32

Frequently Asked Questions

What is Alnylam Pharmaceuticals' business model?

Alnylam Pharmaceuticals operates as a biopharmaceutical company focused on discovering, developing, and commercializing RNA interference (RNAi) therapies for rare diseases. With a market cap of $35.6 billion and trailing P/E of 46.28, the model emphasizes innovation in gene silencing to generate revenue from approved therapies and pipeline advancements.

What are Alnylam's primary revenue sources?

Revenue primarily comes from commercial sales of RNAi-based therapies, with TTM revenue at $4.8 billion and 66.9% quarterly growth. The company reports no dividend yield, focusing instead on product sales and potential licensing in the biotechnology sector.

What competitive advantages does ALNY have?

ALNY's competitive edge stems from its pioneering RNAi platform, strong EPS of $5.75, and high return on equity of 96.6%. With 7 strong buy analyst ratings and a $370.20 target price, its specialized expertise and pipeline depth differentiate it from broader biotech peers.

What are the key risks for ALNY investors?

Key risks include regulatory approval delays, competition in RNAi therapies, and macro headwinds impacting biotech valuations. The stock's 52-week range of $197.81 to $495.55 highlights volatility, though mitigations like 101.7% institutional ownership provide some stability.

What is the growth outlook for ALNY?

The growth outlook is positive, driven by 66.9% revenue growth and analyst consensus favoring expansion in RNAi applications. With forward P/E of 20.7 and latest quarter ending June 2026, continued pipeline success could support further upside toward the $370 target.